140 related articles for article (PubMed ID: 18475294)
1. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Khan OA; Ranson M; Michael M; Olver I; Levitt NC; Mortimer P; Watson AJ; Margison GP; Midgley R; Middleton MR
Br J Cancer; 2008 May; 98(10):1614-8. PubMed ID: 18475294
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
Sabharwal A; Corrie PG; Midgley RS; Palmer C; Brady J; Mortimer P; Watson AJ; Margison GP; Middleton MR
Cancer Chemother Pharmacol; 2010 Oct; 66(5):829-35. PubMed ID: 20039040
[TBL] [Abstract][Full Text] [Related]
4. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic resistance in anaplastic astrocytoma cell lines treated with a temozolomide-lomeguatrib combination.
Ugur HC; Taspinar M; Ilgaz S; Sert F; Canpinar H; Rey JA; Castresana JS; Sunguroglu A
Mol Biol Rep; 2014 Feb; 41(2):697-703. PubMed ID: 24368590
[TBL] [Abstract][Full Text] [Related]
6. O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Watson AJ; Middleton MR; McGown G; Thorncroft M; Ranson M; Hersey P; McArthur G; Davis ID; Thomson D; Beith J; Haydon A; Kefford R; Lorigan P; Mortimer P; Sabharwal A; Hayward O; Margison GP
Br J Cancer; 2009 Apr; 100(8):1250-6. PubMed ID: 19367283
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
Kefford RF; Thomas NP; Corrie PG; Palmer C; Abdi E; Kotasek D; Beith J; Ranson M; Mortimer P; Watson AJ; Margison GP; Middleton MR
Br J Cancer; 2009 Apr; 100(8):1245-9. PubMed ID: 19367282
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
Tawbi HA; Villaruz L; Tarhini A; Moschos S; Sulecki M; Viverette F; Shipe-Spotloe J; Radkowski R; Kirkwood JM
Br J Cancer; 2011 Sep; 105(6):773-7. PubMed ID: 21811257
[TBL] [Abstract][Full Text] [Related]
9. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
10. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
13. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer.
Amatu A; Barault L; Moutinho C; Cassingena A; Bencardino K; Ghezzi S; Palmeri L; Bonazzina E; Tosi F; Ricotta R; Cipani T; Crivori P; Gatto R; Chirico G; Marrapese G; Truini M; Bardelli A; Esteller M; Di Nicolantonio F; Sartore-Bianchi A; Siena S
Ann Oncol; 2016 Jun; 27(6):1062-1067. PubMed ID: 26916096
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
Bafaloukos D; Tsoutsos D; Kalofonos H; Chalkidou S; Panagiotou P; Linardou E; Briassoulis E; Efstathiou E; Polyzos A; Fountzilas G; Christodoulou C; Kouroussis C; Iconomou T; Gogas H
Ann Oncol; 2005 Jun; 16(6):950-7. PubMed ID: 15829494
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter.
Hochhauser D; Glynne-Jones R; Potter V; Grávalos C; Doyle TJ; Pathiraja K; Zhang Q; Zhang L; Sausville EA
Mol Cancer Ther; 2013 May; 12(5):809-18. PubMed ID: 23443801
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Gabrielson A; Tesfaye AA; Marshall JL; Pishvaian MJ; Smaglo B; Jha R; Dorsch-Vogel K; Wang H; He AR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1073-9. PubMed ID: 26449224
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
Rizzieri D; LoRusso S; Tse W; Khan K; Advani A; Moore J; Karsten V; Cahill A; Gerson SL
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):211-6. PubMed ID: 20511167
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
